These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 32795840)

  • 1. The integrated model of glutamate and dopamine hypothesis for schizophrenia: Prediction and personalized medicine for prevent potential treatment-resistant patients.
    Huang LC; Lin SH; Tseng HH; Chen KC; Yang YK
    Med Hypotheses; 2020 Oct; 143():110159. PubMed ID: 32795840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Neurobiological Underpinnings of Obsessive-Compulsive Symptoms in Psychosis, Translational Issues for Treatment-Resistant Schizophrenia.
    Vellucci L; Ciccarelli M; Buonaguro EF; Fornaro M; D'Urso G; De Simone G; Iasevoli F; Barone A; de Bartolomeis A
    Biomolecules; 2023 Aug; 13(8):. PubMed ID: 37627285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine Imbalance as a Biomarker of Treatment-Resistant Schizophrenia.
    Shnayder NA; Khasanova AK; Strelnik AI; Al-Zamil M; Otmakhov AP; Neznanov NG; Shipulin GA; Petrova MM; Garganeeva NP; Nasyrova RF
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate.
    Stahl SM
    CNS Spectr; 2018 Jun; 23(3):187-191. PubMed ID: 29954475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment-Resistant Schizophrenia: Genetic and Neuroimaging Correlates.
    Vita A; Minelli A; Barlati S; Deste G; Giacopuzzi E; Valsecchi P; Turrina C; Gennarelli M
    Front Pharmacol; 2019; 10():402. PubMed ID: 31040787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations in glutamatergic signaling in the brain of dopamine supersensitivity psychosis and non-supersensitivity psychosis model rats.
    Oda Y; Fujita Y; Oishi K; Nakata Y; Takase M; Niitsu T; Kanahara N; Shirayama Y; Hashimoto K; Iyo M
    Psychopharmacology (Berl); 2017 Oct; 234(20):3027-3036. PubMed ID: 28744562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential role of lamotrigine in schizophrenia.
    Large CH; Webster EL; Goff DC
    Psychopharmacology (Berl); 2005 Sep; 181(3):415-36. PubMed ID: 16001126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutamatergic agents for schizophrenia: current evidence and perspectives.
    Zink M; Correll CU
    Expert Rev Clin Pharmacol; 2015 May; 8(3):335-52. PubMed ID: 25916667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does the dopamine hypothesis explain schizophrenia?
    Lau CI; Wang HC; Hsu JL; Liu ME
    Rev Neurosci; 2013; 24(4):389-400. PubMed ID: 23843581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutamate metabolites in treatment resistant schizophrenia: A meta-analysis and systematic review of
    Kumar V; Manchegowda S; Jacob A; Rao NP
    Psychiatry Res Neuroimaging; 2020 Jun; 300():111080. PubMed ID: 32279055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Membrane lipids in schizophrenia and early phases of psychosis: Potential biomarkers and therapeutic targets?].
    Frajerman A; Kebir O; Chaumette B; Tessier C; Lamazière A; Nuss P; Krebs MO
    Encephale; 2020 Jun; 46(3):209-216. PubMed ID: 32151446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The glutamate hypothesis of schizophrenia: neuroimaging and drug development.
    Egerton A; Stone JM
    Curr Pharm Biotechnol; 2012 Jun; 13(8):1500-12. PubMed ID: 22283750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine-glutamate interaction and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosis.
    de Bartolomeis A; Fiore G; Iasevoli F
    Curr Pharm Des; 2005; 11(27):3561-94. PubMed ID: 16248808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-episode psychosis in treatment-resistant schizophrenia: a cross-sectional study of a long-term follow-up cohort.
    Kanahara N; Yamanaka H; Suzuki T; Takase M; Iyo M
    BMC Psychiatry; 2018 Sep; 18(1):274. PubMed ID: 30176881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vulnerable combinations of functional dopaminergic polymorphisms to late-onset treatment resistant schizophrenia.
    Oishi K; Kanahara N; Takase M; Oda Y; Nakata Y; Niitsu T; Ishikawa M; Sato Y; Iyo M
    PLoS One; 2018; 13(11):e0207133. PubMed ID: 30408108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia.
    Suzuki T; Kanahara N; Yamanaka H; Takase M; Kimura H; Watanabe H; Iyo M
    Psychiatry Res; 2015 Jun; 227(2-3):278-82. PubMed ID: 25863824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Music rhythm perception and production relate to treatment response in schizophrenia.
    Honda S; Matsushita K; Noda Y; Tarumi R; Nomiyama N; Tsugawa S; Nakajima S; Mimura M; Fujii S
    Schizophr Res; 2023 Feb; 252():69-76. PubMed ID: 36634450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the brink of precision medicine for psychosis: Treating the patient, not the disease: A commentary on: Association between serum levels of glutamate and neurotrophic factors and response to clozapine treatment by Krivoy et al. 2017.
    Demjaha A
    Schizophr Res; 2018 Mar; 193():487-488. PubMed ID: 28821358
    [No Abstract]   [Full Text] [Related]  

  • 20. A critique of the dopamine hypothesis of schizophrenia and psychosis.
    Moncrieff J
    Harv Rev Psychiatry; 2009; 17(3):214-25. PubMed ID: 19499420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.